Popular Articles

Pfizer Discontinues Phase 3 Trial Of Sutent(R) In Metastatic Colorectal Cancer
Pfizer Inc announced the discontinuation of the SUN 1122 Phase 3 trial that evaluated Sutent® (sunitinib malate) plus FOLFIRI (irinotecan plus infusional 5-fluorouracil and leucovorin) versus FOLFIRI alone for the first-line treatment of metastatic colorectal cancer (CRC). The independent Data Monitoring Committee (DMC) found that the addition of sunitinib to the chemotherapy regimen FOLFIRI would be unable to demonstrate a statistically significant improvement in the primary endpoint of progression-free survival (PFS) compared to FOLFIRI alone, in this study. No new safety issues were identified.
generic viagra online
Gene Test Determines Transplant Drug Tolerance
A simple genetic test can determine a kidney transplant patient"s tolerance for a potent anti-rejection medication, according to an upcoming study in the Journal of the American Society Nephrology (JASN). The test could allow doctors to individualize each patient"s dose, optimizing the drug"s benefits and minimizing its side effects.
News of the day
Michigan Legislature Considering Insurance Reform Bills
"There"s support in Michigan"s Legislature for eliminating insurance practices that deny coverage and charge high rates for people with chronic health problems. But the Michigan reforms face a tight timetable as lawmakers focus on the state"s worsening budget crisis," The Detroit Free Press reports. One Republican plan in the state Senate would address the problem of lost coverage from rising unemployment in Michigan by requiring "businesses -- including self-insured enterprises such as General Motors Corp. and Chrysler Group LLC, now exempt from state regulations, -- to pay to expand health care for poor people. The Detroit Regional Chamber and others oppose new taxes in the Senate plan, particularly when so many businesses are hurting" (Anstett, 7/6).
Health Insurance

White House Reassures Drug CEOs: Reimportation Could Be 'Unnecessary'

The Wall Street Journal reports: "Industry representatives met at the White House Tuesday with officials to consider specifics of a cost-saving agreement the industry reached last month with health-care negotiators and to discuss other concerns that the pharmaceutical industry has with the larger health-care overhaul being considered by Congress. As a presidential candidate, President Barack Obama endorsed re-importation, an idea the industry opposes. White House officials have told the industry if the larger health care bill passes, the cost savings will be so great that reimportation will be unnecessary, according to Billy Tauzin, president of the Pharmaceutical Research and Manufacturers of America." Some of the pharmaceutical companies represented at the Tuesday meeting included Merck & Co., Pfizer Inc., Amgen Inc., Abbott Laboratories and AstraZeneca. The Wall Street Journal notes: "Sen. Bernie Sanders, an independent from Vermont, said he disagrees with any move to drop the reimportation idea. He has pushed to import drugs from Canada, where they are cheaper because of price controls" (Mundy, 7/7). Roll Call: "With the White House and the Senate Finance Committee still trying to figure out how to pay for health care reform, the drug industry is trying to solidify its contributions to the effort. Pharmaceutical Research and Manufacturers of America CEO Billy Tauzin and five member- company CEOs went to the White House on Tuesday afternoon to solidify the $80 billion deal they recently struck with the White House and Senate Finance Chairman Max Baucus (D-Mont.) ... The meeting follows reports that the Congressional Budget Office is expected to score the drug companies" deal as less than the advertised $80 billion in savings, according to several health care lobbyists" (Palmer, 7/8). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):